Effects of Lutein on Learning and Memory in Chronically Stressed Subjects and in an Acute Stressful Situation (TSST - Trier Social Stress Test): A Randomized, Double-blind, Placebo-controlled Trial)
NCT ID: NCT02257801
Last Updated: 2016-01-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
150 participants
INTERVENTIONAL
2013-01-31
2014-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Vitamin (VIT) for Vigilance Study
NCT05574530
Effects of Caffeine and L-Theanine on Physical and Cognitive Performance in Trained Athletes
NCT07268573
Effect of 4 Weeks Supplementation of a Combination of Vitamin Bs and Taurine on Mental Performance in Healthy Adults
NCT05733364
Effects Of Daily Taurine Intake For 6 Months On Biological Age and Body Metabolism Indicators As Well As Physical Fitness In 55-75-year-old Women And Men
NCT06613542
Effects of Microencapsulated Sublingual Glycine (Bidicin) on Cognitive Performance in Healthy Men After an Acute Stressor
NCT03353441
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
SUPPORTIVE_CARE
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Nutritional beverage fortified with 6mg lutein/day
Nutritional beverage fortified with 6mg lutein/day
2 beverages (each containing 3mg lutein) per day (total of 6mg lutein/day) for a total of 4 months
Nutritional beverage fortified with 12mg lutein/day
Nutritional beverage fortified with 12mg lutein/day
2 beverages (each containing 6mg lutein) per day (total 12mg lutein/day) for a total of 4 months
Nutritional beverage fortified with 0mg lutein/day
Nutritional beverage fortified with 12mg lutein/day
2 beverages (each containing 0mg lutein) per day (total 0mg lutein/day) for a total of 4 months
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Nutritional beverage fortified with 6mg lutein/day
2 beverages (each containing 3mg lutein) per day (total of 6mg lutein/day) for a total of 4 months
Nutritional beverage fortified with 12mg lutein/day
2 beverages (each containing 6mg lutein) per day (total 12mg lutein/day) for a total of 4 months
Nutritional beverage fortified with 12mg lutein/day
2 beverages (each containing 0mg lutein) per day (total 0mg lutein/day) for a total of 4 months
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subjects perceiving themselves as chronically stressed and as verified by the TICS questionnaire with scores \> 18 and \< 48.
* Subject is willing to maintain his or her habitual diet and physical activity patterns throughout the study period
* Subject has a body mass index (BMI) of ≥ 18.50 and ≤ 32.00 kg/m2 at screening.
* Subject is willing to abstain from consuming alcoholic drinks 24 h and from consuming caffeine and caffeine containing products 12 h prior to test days until the end of each visit
* Subject is willing to refrain from heavy physical activity 12 h prior to test days
* Subject finds the taste of the nutritional drink acceptable and is willing to consume 2 drinks per day for the whole study duration
* Subject understands the study procedures and signs the informed consent to participate in the study
Exclusion Criteria
* Subject has a positive breath alcohol (as a test for alcohol consumption) or breath carbon monoxide (as test for smoking habits and to exclude smokers) at screening or at any of the admission days
* Subject has any health conditions that would prevent from fulfilling the study requirements, put the subject at risk or would confound the interpretation of the study results as judged by the Investigator on the basis of medical history and routine laboratory test results
* Subjects with a history of renal or hepatic disease that is likely to interfere with the metabolism or excretion of the test product
* Subject has donated more than 300 mL of blood during the last three months prior to screening
* Subject has uncontrolled hypertension (systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥100 mm Hg) at screening
* Subject has a history of psychological illness or condition that interferes with the subject's ability to understand the requirements of the study
* Subject has Diabetes Mellitus
* Subject has a history/ presence of cancer during the last two years (excluding non-melanoma skin cancer)
* Excessive caffeine consumption (\>400 mg caffeine/d or ≥4 cups of caffeinated coffee/d), following screening and throughout the study period
* Use of antibiotics or signs of active systemic infections. Treatment visits might be rescheduled
* Subject is on any medication (with the exception of contraception and short-term use of pain treatment e.g. against headache (i.e. 1-2 day use of analgetics such as Paracetamol or ASS) as well as persistent (for at least three months) and well-adjusted medication (e.g. thyroid and blood pressure medication) with no influence on study outcome as judged by the investigator)
* Subject is currently on a regular oral nutrition solution such as Ensure®, Boost® or similar products. Regular is defined as one or more bottles/ cans per day average consumption over the last 10 or more days
* Subjects who are on a significant hypocaloric diet aiming for significant weight loss
* Use of dietary supplements containing any of the following: lutein, ginkgo biloba, St. John's wort, ginseng, gotu kola (Indian pennywort); daily doses of vitamin E (≥30 mg/d) or folic acid (≥400 μg/d); thiamine, riboflavin, and/or pyridoxine (≥2 mg/d); and eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) or a combination of EPA + DHA (≥500 mg/d) within 2 weeks prior to screening
* Subject is a vegetarian
* Subject has had exposure to any non-registered drug product within 30 days prior to the screening visit
* Recent history of (within 12 months of screening visit) or strong potential for alcohol or substance abuse. Alcohol abuse is defined as \> 60g (men)/ 40g (women) pure alcohol per day (1.5 l / 1 l beer resp. 0.75 l / 0.5 l wine)
* Subject has a known allergy or sensitivity to the study product or any ingredients of the study product or meals provided, especially against soy and milk protein
* Subject is pregnant, planning to be pregnant during the study period, lactating, or women of childbearing potential who are unwilling to commit to the use of a medically approved form of contraception throughout the study period. The method of contraception must be recorded in the source documentation
* Subject is unable to perform the tests on the CANTAB system during training as being flagged by the software
50 Years
70 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
DSM Nutritional Products, Inc.
INDUSTRY
Abbott Nutrition
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Michael Clemens, MD
Role: PRINCIPAL_INVESTIGATOR
DAaCRO GmbH
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
DAaCRO GmbH
Trier, Trier, Germany
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2011-11-02-LUTE / D1-2011
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.